The latest price target for Pfizer (NYSE:PFE) was reported by Guggenheim on February 10, 2025. The analyst firm set a price target for $33.00 expecting PFE to rise to within 12 months (a possible 27.02% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Pfizer (NYSE:PFE) was provided by Guggenheim, and Pfizer reiterated their buy rating.

The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.

The last downgrade for Pfizer Inc happened on March 22, 2024 when Argus Research changed their price target from N/A to N/A for Pfizer Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on February 10, 2025 so you should expect the next rating to be made available sometime around February 10, 2026.

While ratings are subjective and will change, the latest Pfizer (PFE) rating was a reiterated with a price target of $33.00 to $33.00. The current price Pfizer (PFE) is trading at is $25.98, which is out of the analyst’s predicted range.